NanoViricides begins Phase II trial of NV-387 oral gummies for mpox in Congo

• NanoViricides began a Phase II trial of NV-387 oral gummies for mpox, enrolling the first patients in the Democratic Republic of Congo.
• No clinical results have been presented; the study is designed to generate future safety and efficacy readouts.
• Trial compares NV-387 with standard of care in patients with clinical mpox and confirmed or presumptive infection, using an adaptive randomized open-label design.
• Move targets a market with no approved mpox treatment, following prior tecovirimat trials that failed to show benefit in mpox.
• Company positioned the program as a potential pathway toward US pandemic-response procurement if Phase II results support further development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609230830ACCESSWRNAPR_____1225803) on September 23, 2026, and is solely responsible for the information contained therein.